Nektar Therapeutics (NKTR) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Nektar Therapeutics (NKTR) Q1 2026: Phase 3 Readiness Advances, 9-12 Month Durability Data in Focus
May 08, 2026
-
Nektar Therapeutics (NKTR) Q4 2025: Cash Surges to $476M, Accelerating Phase III Immunology Push
March 13, 2026
-
Nektar Therapeutics (NKTR) Q3 2025: Cash Runway Extended to Q2 2027 as RESPEG Differentiation Deepens
November 07, 2025
-
Nektar Therapeutics (NKTR) Q2 2025: $115M Raise Extends Runway, RESPEG Poised for Phase 3 in $15B Derm Market
August 08, 2025